Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints cancer immunotherapy experts

Ronald Levy, Zelig Eshhar and Inder Verma will offer expert advice to US biotech

Ronald Levy, Kite Pharma Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.

Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.

Their expertise will help the US biotech develop medicines that activate the body's T cells to fight tumours.

Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.

"Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said Dr Aya Jakobovits, president and CEO of Kite.

Article by
Thomas Meek

12th August 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics